This database contains 523 studies, archived under the term: "Alzheimer’s Disease"
Click here to filter this large number of results.
An open-label, nonplacebo-controlled study on Cistanche tubulosa glycoside capsules (Memoregain(®)) for treating moderate Alzheimer’s Disease
Guo, Qihao,
Zhou, Yan,
Wang, Chao-Jih,
Huang, Young-Ming,
Lee, Yi-Ta,
Su, Muh-Hwan,
Lu, Jiahong
Aim: Efficacy and safety of Cistanche tubulosa glycoside capsules (CTG capsule, Memoregain(®)) for treating Alzheimer’s disease (AD) were studied.; Methods: A total of 18 patients with AD administered with Memoregain(®) for 48 weeks were assessed for drug efficacy by Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog), Mini-Mental State Examination (MMSE), Activities of Daily Living (ADLs), Blessed […]
Treadmill training as an augmentation treatment for Alzheimer’s disease: a pilot randomized controlled study
Arcoverde, Cynthia,
Deslandes, Andrea,
Moraes, Helena,
Almeida, Cloyra,
Araujo, Narahyana Bom de,
Vasques, Paulo Eduardo,
Silveira, Heitor,
Laks, Jerson
Objective: To assess the effect of aerobic exercise on the cognition and functional capacity in Alzheimer’s disease (AD) patients.; Method: Elderly (n=20) with mild dementia (NINCDS-ADRDA/CDR1) were randomly assigned to an exercise group (EG) on a treadmill (30 minutes, twice a week and moderate intensity of 60% VO₂max) and control group (GC) 10 patients. The […]
Effect of compound Polygonum multiflorum extract on Alzheimer’s disease
Objective: To observe the clinical effect of compound Polygonum multiflorum extract on Alzheimer’s disease (AD).; Methods: We collected 209 AD patients, among whom 120 were treated with compound Polygonum multiflorum extract as a treatment group, 60 were treated with Polygonum multiflorum extract as a Chinese herb control group, and 29 were treated with Naofukang as […]
A 22-week, multicenter, randomized, double-blind controlled trial of Crocus sativus in the treatment of mild-to-moderate Alzheimer’s disease
Akhondzadeh, Shahin,
Shafiee Sabet, Mehdi,
Harirchian, Mohammad Hossein,
Togha, Mansoreh,
Cheraghmakani, Hamed,
Razeghi, Soodeh,
Hejazi, Seyyed Shamssedin,
Yousefi, Mohammad Hossein,
Alimardani, Roozbeh,
Jamshidi, Amirhossein,
Rezazadeh, Shams-Ali,
Yousefi, Aboulghasem,
Zare, Farhad,
Moradi, Atbin,
Vossoughi, Ardalan
Rationale: There is increasing evidence to suggest the possible efficacy of Crocus sativus (saffron) in the management of Alzheimer’s disease (AD).; Objective: The purpose of the present investigation was to assess the efficacy of C. sativus in the treatment of patients with mild-to-moderate AD.; Methods: Fifty-four Persian-speaking adults 55 years of age or older who […]
Saffron in the treatment of patients with mild to moderate Alzheimer’s disease: a 16-week, randomized and placebo-controlled trial
Akhondzadeh, S.,
Sabet, M. Shafiee,
Harirchian, M. H.,
Togha, M.,
Cheraghmakani, H.,
Razeghi, S.,
Hejazi, S. Sh,
Yousefi, M. H.,
Alimardani, R.,
Jamshidi, A.,
Zare, F.,
Moradi, A.
What Is Known: Herbal medicines have been used in the treatment of behavioural and psychological symptoms of dementia but with variable response. Crocus sativus (saffron) may inhibit the aggregation and deposition of amyloid β in the human brain and may therefore be useful in Alzheimer’s disease (AD).; Objective: The goal of this study was to […]
Ibuprofen treatment modifies cortical sources of EEG rhythms in mild Alzheimer’s disease
Babiloni, Claudio,
Frisoni, Giovanni B.,
Del Percio, Claudio,
Zanetti, Orazio,
Bonomini, Cristina,
Cassetta, Emanuele,
Pasqualetti, Patrizio,
Miniussi, Carlo,
De Rosas, Mario,
Valenzano, Anna,
Cibelli, Giuseppe,
Eusebi, Fabrizio,
Rossini, Paolo M.
Objective: Non-steroidal anti-inflammatory drugs such as ibuprofen have a protective role on risk of Alzheimer’s disease (AD). Here we evaluated the hypothesis that long-term ibuprofen treatment affects cortical sources of resting electroencephalographic (EEG) rhythms in mild AD patients.; Methods: Twenty-three AD patients (13 treated AD IBUPROFEN; 10 untreated AD PLACEBO) were enrolled. Resting EEG data […]
The fitness for the Ageing Brain Study II (FABS II): protocol for a randomized controlled clinical trial evaluating the effect of physical activity on cognitive function in patients with Alzheimer’s disease
Cyarto, Elizabeth V.,
Cox, Kay L.,
Almeida, Osvaldo P.,
Flicker, Leon,
Ames, David,
Byrne, Gerard,
Hill, Keith D.,
Beer, Christopher D.,
LoGiudice, Dina,
Appadurai, Kana,
Irish, Muireann,
Renehan, Emma,
Lautenschlager, Nicola T.
Background: Observational studies have documented a potential protective effect of physical exercise in older adults who are at risk for developing Alzheimer’s disease. The Fitness for the Ageing Brain II (FABS II) study is a multicentre randomized controlled clinical trial (RCT) aiming to determine whether physical activity reduces the rate of cognitive decline among individuals […]
Alzheimer’s Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results
Background: The Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT) was designed to address whether non-steroidal anti-inflammatory drugs (NSAIDs) can prevent or delay the onset of Alzheimer’s disease (AD).; Methods: ADAPT was a randomized, double-placebo-controlled, multicenter chemoprevention trial conducted at six U.S. dementia research clinics. At entry, participants were required to test “normal” on a battery of […]